Defunct Company
Total Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
174
NCT00867607
Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis
Phase: Phase 1/2
Role: Collaborator
Start: Mar 31, 2011
Completion: Mar 31, 2014
NCT03827200
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 11, 2019
Completion: Jan 21, 2021
NCT04771000
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Start: Feb 8, 2021
Completion: Feb 27, 2023
NCT06256432
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Start: Apr 17, 2024
Completion: Feb 28, 2026